Stocks · News reference

Decoy Therapeutics shares are trading lower. The company announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute.

Jul 27, 2026, 5:58 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 7, 2026, 3:06 PMBenzinga Newsdesk
U.S. CDC Says As Of August 6, 2,465 Confirmed Measles Cases Were Reported In U.S. In 2026; There Have Been 38 New Measles Outbreaks Reported In 2026, And 94% Of Confirmed Cases Are Outbreak-Associated
https://www.cdc.gov/measles/data-research/index.html
Read original at benzinga
DCOY EBS GSK MRK PFE
BenzingaAug 3, 2026, 1:05 PMBenzinga Newsdesk
Decoy Therapeutics Announces The Expansion Of Its Intellectual Property Portfolio, Which Now Comprises Seven Patent Families
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform
Read original at benzinga
DCOY
BenzingaJul 27, 2026, 1:04 PMBenzinga Newsdesk
Decoy Therapeutics Announces That One Of Its D-MAV Candidates Demonstrates In Vitro Activity Against Wild-Type Ebola Zaire Virus
Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg. The candidate was engineered on Decoy's IMP3ACT™ platform to block coronavirus
Read original at benzinga
DCOY